Find Academic Supervisors

Michael WatersView profile

Assistant Professor

• Radiation Oncology
• Thoracic Oncology
• Gastrointestinal Oncology
• +7 more

Michael Waters, MD, PhD is an Assistant Professor of Radiation Oncology at Washington University School of Medicine in St. Louis, with clinical specialization in Thoracic and Gastrointestinal radiation oncology. His work integrates advanced radiation techniques including Stereotactic Body Radiotherapy (SBRT) and Gamma Knife radiosurgery with cutting-edge computational approaches. Dr. Waters' research focuses on applying deep learning, machine learning, and genomics to radiation oncology challenges. His work spans multiple cancer types including lung, pancreatic, prostate, and breast cancers, with particular emphasis on improving treatment precision through adaptive radiotherapy and AI-driven decision support. Current projects include developing generative AI tools for gene expression analysis (GAiN) and implementing large language models to streamline clinical workflows and insurance appeals. His publication record shows consistent productivity with 35 research outputs since 2015, accelerating to 10 publications in 2024-2025. Recent work demonstrates growing influence in AI applications for radiation oncology , with studies on CT-based adaptive therapy for prostate cancer, MR-guided SBRT for pancreatic tumors, and ethical considerations for AI in clinical trial communication. His research has been presented at major conferences including ASTRO, ASCO, and AACR. Dr. Waters completed his MD/PhD at Virginia Commonwealth University (2019), residency in Radiation Oncology at Washington University (2024), and maintains active roles at Siteman Cancer Center and the Institute of Clinical and Translational Sciences (ICTS). His work bridges clinical radiation oncology with computational biology, creating novel approaches to personalize cancer treatment through data-driven methodologies.

• Clinical Cancer Epidemiology
• Precision Oncology
• Artificial Intelligence Safety and Ethics
• +3 more

Ashley Hopkins is an Associate Professor at the College of Medicine and Public Health , Flinders University. As leader of the Clinical Cancer Epidemiology Lab and a National Breast Cancer Foundation of Australia Postdoctoral Fellow, they bridge precision oncology with artificial intelligence ethics research. Flinders Health and Medical Research Institute Precision Medicines Group Flinders Centre for Innovation in Cancer Research Interests focus on clinical cancer epidemiology and pharmacometric modeling to create actionable prediction strategies for advanced cancer patients. Their work spans: Clinical Prediction Models Big Data Analysis from pharmaceutical trials AI Safety & Ethics Immunotherapy and Targeted Therapy Evaluation Breast/Lung/Colorectal Cancer Research Health Disinformation Mitigation Scientific Awards include: NHMRC Investigator (2022-2026) SA Young Investigator Tall Poppy (2021) Certara New Investigator Award (2020) Vice-Chancellor’s Award for ECRs (2019) Publications highlight trends in: AI application in oncology communication Ethical implications of autonomous AI in medicine Hyperprogressive disease analysis in hepatocellular carcinoma Reliability of AI chatbots for cancer information Supervision Opportunities exist for PhD/Honours students with backgrounds in pharmacy, medical sciences, or biostatistics interested in precision oncology, clinical epidemiology, or ethical AI implementation.

Amy BohnertView profile

Professor

• Substance Use
• Opioid Use Disorder
• Pharmacoepidemiology
• +5 more

Amy Bohnert, PhD, MHS, is Professor in the Department of Anesthesiology (primary), Psychiatry, and Epidemiology at the University of Michigan and Research Investigator at the VA Center for Clinical Management Research. Her work addresses substance use disorders, mental health interventions, and long-term disease outcomes with emphasis on Veteran populations. Her educational background includes: PhD in Mental Health, Johns Hopkins Bloomberg School of Public Health MHS in Mental Health, Johns Hopkins Bloomberg School of Public Health BA (dual) in English and Psychology, University of Maryland, College Park Dr. Bohnert's research centers on substance use epidemiology and opioid use disorder , utilizing digital health interventions and pharmacoepidemiology . She leads the PROviding Mental health Precision Treatment (PROMPT) initiative using mobile/wearable technology; PowerED, a reinforcement learning-optimized trial for opioid misuse; the Michigan Opioid Collaborative expanding addiction treatment access; and the VA COVID-19 Observational Research Collaboratory studying long-term pandemic impacts on Veterans. Her methodology emphasizes target trial emulation and pragmatic trials with VA/claims data. Analysis of her 2022-2025 publications reveals dominant themes in opioid policy evaluation (naloxone/buprenorphine access, PDMP impacts), mental health outcomes post-COVID-19, and cannabis for chronic pain in Veterans. Her work consistently addresses health disparities and employs advanced epidemiological techniques to inform clinical practice and health policy. Dr. Bohnert mentors students in epidemiology and public health through the University of Michigan's Precision Health initiative. Her research is grant-funded through VA and federal sources focusing on substance use and Veterans' health services. She actively contributes to the Michigan Veterans Cannabis Program applying community-based participatory research to assess cannabis effectiveness for pain management.

• Rheumatology
• Systemic Lupus Erythematosus
• Autoimmunity
• +5 more

Roberto Caricchio, MD is a Professor and holds the Myles J. McDonough Chair in Rheumatology at UMass Chan Medical School. He serves in multiple capacities across the institution, including in the Department of Medicine (Division of Rheumatology) at the T.H. Chan School of Medicine, and in several departments within the Morningside Graduate School of Biomedical Sciences including Immunology and Microbiology Program, Interdisciplinary Graduate Program, MD/PhD Program, and Translational Science. Dr. Caricchio received his MD from Catholic University in Rome, Italy. His extensive academic career has focused on rheumatology and autoimmune diseases, particularly Systemic Lupus Erythematosus (SLE). Dr. Caricchio's research primarily centers on the immunopathogenesis of autoimmune diseases, with special emphasis on Systemic Lupus Erythematosus. His work explores the mechanisms of cytokine storms, the role of bacterial infections in triggering autoimmunity, and the immunological basis of lupus nephritis. Recent research has expanded to include the intersection of autoimmune diseases and COVID-19, examining how viral infections can exacerbate autoimmune conditions and studying vaccine responses in immunosuppressed patients. His publication record demonstrates a strong focus on translational research, with numerous studies bridging basic immunological mechanisms to clinical applications. Recent work has particularly emphasized the role of bacterial biofilms, curli/DNA complexes, and endogenous retroviruses in lupus pathogenesis, as well as innovative therapeutic approaches including CAR T cell therapy for autoimmune conditions. Dr. Caricchio has collaborated extensively with researchers across multiple institutions, contributing to significant advancements in understanding autoimmune mechanisms and developing novel treatment approaches for lupus and related conditions. His work has been supported by various research grants, though specific funding sources are not detailed in the provided information. He has mentored numerous students and researchers through his roles in graduate programs, though specific names of advisees are not provided in the current data. Dr. Caricchio's laboratory and research team focus on understanding the immunological mechanisms underlying lupus and other autoimmune diseases, with particular attention to the role of bacterial triggers, cytokine networks, and sex differences in disease manifestation.

• Medical Oncology
• Pharmacology
• Palliative Care
• +1 more

Annemieke van der Padt - Pruijsten is a researcher in the Department of Medical Oncology at Erasmus MC, Erasmus University Rotterdam. Her work focuses on advancing cancer treatment through precision dosing strategies and pharmacokinetic studies. Research interests include: Model-informed precision dosing for hormonal therapies in breast cancer Pharmacokinetic interactions of anticancer drugs with common medications Development and implementation of palliative care pathways for advanced cancer patients Recent publications highlight her contributions to optimizing tamoxifen therapy, understanding drug transporter interactions (OCT2/MATE1), and evaluating palliative care quality from bereaved relatives' perspectives.

Nikolai J. MickeviciusView profile

Assistant Professor

• Magnetic Resonance Imaging
• Biophysics
• Medical Imaging
• +3 more

Nikolai J. Mickevicius, PhD, is an Assistant Professor in the Department of Biophysics at the Medical College of Wisconsin (MCW). He holds a PhD in Biophysics from MCW (2018) and a BS in Biomedical Engineering from the Milwaukee School of Engineering (2013). Prior to his faculty position at MCW, he served as a research scientist in the Department of Radiation Oncology at MCW and completed a Bentson Translational Research Fellowship at the University of Wisconsin–Madison's Department of Human Oncology. His current work focuses on advancing MRI technologies for clinical applications. Education: PhD in Biophysics, Medical College of Wisconsin, 2018 BS in Biomedical Engineering, Milwaukee School of Engineering, 2013 Research Focus: Dr. Mickevicius' laboratory develops cutting-edge MRI pulse sequences and reconstruction algorithms to enhance diagnostic information within clinically feasible scan times. His work emphasizes applications in radiation therapy guidance, real-time motion monitoring, and multi-spectral imaging. Key Research Areas: MRI acceleration techniques Deep learning for image recovery MRI-guided radiation therapy Multi-orientation imaging Publications Overview: His recent work includes advancements in simultaneous multi-orientation MRI, deep learning-driven image reconstruction, and real-time motion management systems for therapeutic applications. These innovations aim to improve diagnostic accuracy and treatment precision in oncology settings. Labs/Teams: He leads a research group focused on translational MRI technologies at MCW, collaborating with oncology and radiology teams to advance clinical imaging solutions.

Klaus Tapio OlkkolaView profile

Professor

• Anesthesiology
• Intensive Care
• Pharmacokinetics
• +4 more

Professor Klaus Tapio Olkkola is a distinguished academic and clinician at the University of Helsinki, serving as Professor of Anesthesiology and Intensive Care and Director of Clinicum. He holds appointments in the Faculty of Medicine, Department of Diagnostics and Therapeutics, and is actively involved in clinical practice at Helsinki University Central Hospital. His leadership extends to supervising doctoral programs in Drug Research and Clinical Research. Bachelor of Medicine (MB), University of Helsinki, 1979 Licentiate in Medicine (MD), University of Helsinki, 1983 Doctor of Medical Science (MScD), University of Helsinki, 1985 Docent in Pharmacology, University of Helsinki, 1991 Docent in Anesthesiology, University of Helsinki, 1995 Special competence in medical education, Finnish Medical Association, 2010 Professor Olkkola's research spans anesthesiology, intensive care, pharmacokinetics, and pharmacodynamics , with particular focus on drug interactions, pain management, and emergency medicine. His work examines how cytochrome P-450 isozymes affect intravenous anesthetics, pharmacogenomics in anesthesia dosing, and management of pain in children. His recent studies have explored ketamine analgo-sedation, propofol requirements influenced by genetics, and physiologically based pharmacokinetic modeling of drug interactions. His scientific contributions have been recognized through multiple awards including Young Scientist's Awards from the Finnish Society of Anaesthesiologists and Scandinavian Society of Anaesthesiologists, the Acta Award, and recognition as a Corresponding Member of the German Society of Anaesthesiology and Intensive Care Medicine. He has served on editorial boards for prestigious journals including the European Journal of Anaesthesiology and Current Opinion in Anaesthesiology. Professor Olkkola has mentored over 20 doctoral students whose work spans diverse areas of anesthesiology and pharmacology. His research has been supported by numerous grants from the Alexander von Humboldt Foundation, Finnish foundations, and pharmaceutical industry. He actively participates in guideline development for major medical societies including the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.

• Cardiovascular Disease
• Heart Failure
• Clinical Trials
• +3 more

Dr. Li Shen is an Honorary Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health, specializing in cardiovascular research with a focus on heart failure mechanisms, clinical outcomes, and therapeutic interventions. His work integrates large clinical trial data (e.g., PARADIGM-HF, PARAGON-HF) to explore treatment efficacy across patient subgroups, including those with diabetes, renal impairment, and comorbidities like cancer. Research interests include prognostic modeling for sudden/pump-failure death, drug safety (e.g., beta-blockers, sacubitril/valsartan), and disparities in heart failure outcomes based on race, gender, and socioeconomic factors. His studies often analyze biomarkers (e.g., prognostic nutritional index) and comorbidities (e.g., diabetes, frailty) to refine patient stratification and treatment strategies. Recent articles highlight advancements in understanding heart failure subtypes (HFrEF/HFpEF), drug interactions in polypharmacy, and the impact of therapies like dapagliflozin in diabetic populations. Collaborations with global research networks (e.g., Swedish Heart Failure Registry) enhance the generalizability of findings. Key contributions include validating predictive models for mortality/morbidity and investigating the declining incidence of sudden cardiac death in heart failure populations over time. This work informs precision medicine approaches and clinical guidelines for optimized heart failure management.

• Radiation Oncology
• Cancer Biology
• Brain Tumors
• +5 more

Aram Modrek is an Assistant Professor of Radiation Oncology and Cancer Biology in the Department of Radiation Oncology at the Keck School of Medicine of the University of Southern California. He serves as Culture and Engagement Champion for the Department and is an active member of the USC Norris Comprehensive Cancer Center, Epigenetic Regulation in Cancer Program, and USC Brain Tumor Center. Dr. Modrek's research centers on DNA damage-induced genomic alterations and their impact on gene regulation in brain tumors, with particular focus on treatment resistance mechanisms. His lab employs cutting-edge genomic and transcriptomic approaches to investigate how cancer cells adapt to therapy, aiming to develop strategies that disrupt these adaptive processes. Key research areas include radiation biology, glioblastoma pathogenesis, epigenetic regulation, and molecular mechanisms of therapeutic resistance. His publication record demonstrates consistent productivity with 15+ recent articles spanning radiation oncology, cancer biology, and neuro-oncology. Research themes prominently feature brain tumor genomics, DNA damage response pathways, and translational applications of molecular findings. Recent work includes investigations into platelet transcriptomes in cancer, radiation resistance mechanisms in glioblastoma, and novel therapeutic targets like PDPN and GPR133. No scientific awards were explicitly mentioned in the source material. Dr. Modrek leads the Modrek Lab with support from external funding sources, though specific grants aren't detailed in the provided text. His work bridges basic science and clinical applications, evidenced by publications spanning molecular mechanisms to clinical decision support tools. The lab operates within USC's robust cancer research infrastructure, collaborating across multiple centers including the Brain Tumor Center. The Modrek Lab functions within the Department of Radiation Oncology at USC, actively participating in the university's cancer research ecosystem through the Norris Comprehensive Cancer Center and specialized programs focused on brain tumors and epigenetic regulation.

• Environmental Health
• Toxicology
• Chemical Biology
• +3 more

Xiaojing Li is a Postdoctoral Researcher in the Department of Precision Environmental Health, focusing on environmental health and toxicology. She leads the 'Precision Environmental Health' project (2024–2027), funded by the Natural Environment Research Council. Her work addresses chemical mixtures, Daphnia biology, and molecular mechanisms in ecotoxicology. Research interests include chemical toxicity, environmental sex determination, and high-throughput testing methodologies. Recent studies explore bioactivity profiling of pollutants, metabolomics in toxicity assessment, and modernizing chemical risk evaluation. She contributes to global sustainable development goals related to clean water and responsible consumption. Key collaborations involve institutions globally, with emphasis on aquatic toxicology and environmental regulation. Her research bridges molecular mechanisms with ecological impacts, aiming to inform policy and chemical safety practices.

• Data Warehousing
• Clinical Data Quality
• Privacy-Preserving Record Linkage
• +5 more

Douglas Bell is a Professor-in-Residence in both Medicine and Computational Medicine at the David Geffen School of Medicine, University of California Los Angeles (UCLA) . With a career spanning over 35 years, he is a leading figure in biomedical informatics, focusing on clinical data quality, patient record linkage, and machine learning applications in healthcare. Education: B.A. in Biochemistry and Computer Science, Case Western Reserve University (1985) M.D., Harvard Medical School (1990) Medical Informatics Fellowship, Harvard-MIT Division of Health Science and Technology (1994) Ph.D. in Health Services, UCLA (2000) His research explores data warehousing , privacy-preserving record linkage , and machine learning in medical diagnosis . He leads UCLA's participation in the National COVID Cohort Collaboration (N3C) and 4CE Consortium , analyzing global EHR data for pandemic response. Recent work includes developing simulation models for chronic kidney disease prediction and improving race-ethnicity data completeness in health records. Key areas in his work include: International EHR data harmonization Reducing alert fatigue in clinical decision support Precision phenotyping for research cohorts Mentoring clinical informatics fellows Addressing health disparities in diabetes care Scientific honors include: Best Poster Award, AMIA (2016) ACMI Fellowship (2007) HHMI/NIH Research Scholar (1988) Phi Beta Kappa (1984) He has trained over 100 clinical informatics fellows and currently serves as Leader of the Informatics Program at UCLA CTSI , advancing biomedical discovery through data science innovation.

• Cancer Genetics
• Colorectal Cancer
• Breast Cancer
• +9 more

Professor Rodney Scott is a leading geneticist at the School of Biomedical Sciences and Pharmacy , University of Newcastle, Australia. He co-directs the Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine , pioneering interdisciplinary research linking bioinformatics with clinical practice to advance personalized medicine. His career spans over 20 years in hereditary cancer research, with global recognition in breast cancer , colorectal cancer , and Lynch syndrome genetics. Education : Privat Dozent (German DSc equivalent), University of Basel; PhD and BSc (Honours), University of Western Australia. Scott’s research focuses on the genetic basis of malignancy , including modifier genes in disease penetrance, epigenetics in multiple sclerosis , and DNA repair mechanisms . His work bridges clinical genetics , bioinformatics , and pharmacogenomics , with recent studies on epigenetic signatures for disease progression and machine learning applications in genomic data analysis. His 15 most recent articles highlight trends in genomic risk modeling , epigenetics , environmental-cancer interactions , and pharmacogenomic testing . Key areas include endometrial and colorectal cancer susceptibility loci , DPYD-guided chemotherapy , and multi-omics approaches to multiple sclerosis and schizophrenia . Scientific Awards : Fellow of the Royal Society of NSW (2017); Honorary PhD from Pomeranian Academy of Medicine (2017); FRCPath (2005); Fellow of Royal College of Pathologists of Australasia (2011). Scott has supervised numerous PhD students and contributes to national committees on genetic services and bioethics . He collaborates extensively with the Hunter Medical Research Institute and international institutions, integrating genomic and clinical data for translational impact.

• Radiation Oncology
• Immunotherapy
• Cancer Immunology
• +6 more

Dr. Andrew Sharabi is a physician scientist and board-certified radiation oncologist at UC San Diego Moores Cancer Center. He holds the position of Clinical Professor in the Department of Radiation Medicine and Applied Science within the School of Health Sciences at the University of California San Diego. Dr. Sharabi serves as Director of the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center and is Chair of the American Society of Therapeutic Radiology and Oncology (ASTRO) Education Committee - Immunotherapy Track. Dr. Sharabi's educational background includes: B.S. in Bioengineering from University of California at San Diego (2001) Ph.D. in Immunology from Baylor College of Medicine (2009) M.D. from Baylor College of Medicine (2010) Residency in Radiation Oncology at Johns Hopkins Hospital (2015) Dr. Sharabi is a recognized expert on the effects of radiation on the immune system and the ability of radiation therapy to synergize with checkpoint blockade immunotherapy. His research focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy, particularly for head and neck cancers and prostate (genitourinary) cancers. He treats patients with advanced radiotherapy techniques including intensity modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), 4-D computed tomography, and Stereotactic Body Radiation Therapy (SBRT). His work has significant implications for improving cancer treatment outcomes through the strategic combination of radiation and immunotherapy. Analysis of Dr. Sharabi's recent publications reveals a strong focus on the intersection of radiation oncology and immunotherapy. His research spans multiple cancer types, with particular emphasis on head and neck squamous cell carcinoma (HNSCC) and genitourinary cancers. Key themes include the sequencing of radiation and immunotherapy, mechanisms of immune activation following radiation, biomarker development for treatment personalization, and strategies to overcome resistance to combined modality therapy. His work frequently appears in high-impact journals including Nature Communications and Lancet Oncology, demonstrating the significance of his contributions to the field. Dr. Sharabi has received numerous prestigious awards and honors throughout his career: Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award (2020) Academy of Clinician Scholars Whitehill Award for Excellence in Teaching (2019) American Cancer Society (ACS) Cancer Care Champion - Radiation Oncologist of the Year (2019) UCSD ACTRI KL2 Translational Science Award (2017) Multiple awards from the American Society for Radiation Oncology (ASTRO) including the Roentgen Resident/Fellow Research Award (2015) As Principal Investigator, Dr. Sharabi leads multiple NIH-funded research projects including 'Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy' (NIH R21CA256360) and 'Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC' (NIH/NIDCR R01DE028563). His research program combines basic science investigations with clinical trials, bridging the gap between laboratory discoveries and patient care. While specific information about his advisees is not provided in the available materials, his leadership roles suggest he mentors numerous students, residents, and fellows in radiation oncology and cancer research. Dr. Sharabi directs the Center for Precision Radiation Medicine and Radiation Medicine Core Facility at Moores Cancer Center, where his NIH-funded laboratory focuses on developing novel immunotherapies and strategies to combine radiation with immunotherapy. His research team likely includes postdoctoral fellows, graduate students, research technicians, and clinical collaborators working across disciplines to advance cancer treatment through innovative combinations of radiation and immunotherapy.

• Biostatistics
• Clinical-trial design
• Pediatric oncology
• +4 more

Yueh-Yun Chi is Professor of Research Pediatrics and Population & Public Health Sciences at the Keck School of Medicine of USC, and Director of the Biostatistics Core for the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles. She provides statistical leadership for the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) and New Approaches to Neuroblastoma Therapy (NANT) consortia, and previously served as lead statistician for the Children’s Oncology Group renal-tumor and soft-tissue committees at the University of Florida. Research Interests Her work spans biostatistical methodology for early-phase and multi-institutional pediatric oncology trials, late-effects & survivorship epidemiology, tumor-induced osteomalacia, and innovative trial-design optimization. She has particular expertise in dose-finding, washout-period optimization, and integration of genomic and metabolomic endpoints into childhood-cancer studies. Publication Trends Chi’s 2023-2025 output is dominated by first- or senior-author papers on relapsed leukemia/lymphoma therapies, neuroblastoma phase I combinations, and large cohort analyses of tumor-induced osteomalacia, illustrating her central role in the design, conduct, and reporting of multicenter pediatric trials. Contact & Resources Email: yuehyunc@usc.edu CTSI faculty profile and USC/CHLA institutional pages provide additional information.

• Pharmacokinetics
• Oncology
• Clinical Pharmacology
• +3 more

Bram Agema is a Researcher at Erasmus MC, specializing in Medical Oncology with a focus on pharmacokinetics and model-informed precision dosing. His work integrates pharmacometrics to optimize drug therapies in oncology and other clinical settings. He holds a doctoral degree from Erasmus University Rotterdam, awarded in June 2025 for his thesis on data-driven dosing strategies in oncology. Key research areas include drug exposure-response relationships, individualized therapy optimization, and predictive modeling of chemotherapy regimens. Recent projects address challenges in transitioning between subcutaneous and transdermal drug administration, nintedanib pharmacokinetics in pulmonary fibrosis, and ensemble modeling for precision dosing. His publications emphasize translational research bridging pharmacokinetic theory to clinical practice, with contributions to journals like Drugs , Journal of Pain and Symptom Management , and Clinical Pharmacokinetics . Collaborations span multidisciplinary teams at Erasmus MC and other institutions, focusing on improving treatment efficacy and safety through advanced dosing strategies.